My research interests are to apply tissue-engineered technologies to study the role of the microenvironment in modulating cancer progression and therapy response. I develop 3D models that mimic the human disease and use this to develop novel therapies.
Functionalization, preparation and use of cell-laden gelatin methacryloyl-based hydrogels as modular tissue culture platforms. Nature Protocols (2016) 11(4): 727-746. PMID: 26985572
Gelatine methacrylamide-based hydrogels: an alternative 3D cancer cell culture system. Acta Biomaterialia (2014) 10(6): 2551-2562. PMID: 24590158
Engineered microenvironments provide new insights into ovarian and prostate cancer progression and drug responses. Advanced Drug Delivery Reviews (2014) 79-80: 193-213. PMID: 24969478
Bioengineered 3D platform to explore cell-ECM interactions and drug resistance of ovarian cancer cells. Biomaterials (2010) 31(32): 8494-8506. PMID: 20709389
My research interests are to understand the role of the extracellular and cellular microenvironment in modulating cancer progression and therapy response applying tissue-engineered technologies.
I am developing bioengineered 3-D platforms that will enable us to:
A humanized bone microenvironment uncovers HIF2 alpha as a latent marker for osteosarcoma. Wagner F, Holzapfel BM, Martine LC et al. Acta Biomater (2019) 89(2) 372-381
A 3D tumor microenvironment regulates cell proliferation, peritoneal growth and expression patterns. Loessner D, Rockstroh A, Shokoohmand A et al. Biomaterials (2019) 190-191(2) 63-75
Humanization of the Prostate Microenvironment Reduces Homing of PC3 Prostate Cancer Cells to Human Tissue-Engineered Bone. McGovern JA, Shafiee A, Wagner F et al. Cancers (Basel) (2018) 10(2)
SpheroidSim-Preliminary evaluation of a new computational tool to predict the influence of cell cycle time and phase fraction on spheroid growth. Little JP, Pettet GJ, Hutmacher DW et al. Biotechnol Prog (2018) 34(2) 1335-1343
Kallikrein-related peptidases 4, 5, 6 and 7 regulate tumour-associated factors in serous ovarian cancer. Wang P, Magdolen V, Seidl C et al. Br J Cancer (2018) 119(2) 1-9
Kallikrein-related peptidases represent attractive therapeutic targets for ovarian cancer. Loessner D, Goettig P, Preis S et al. Expert Opin Ther Targets (2018) 22(1) 745-763
Humanization of bone and bone marrow in an orthotopic site reveals new potential therapeutic targets in osteosarcoma. Wagner F, Holzapfel BM, McGovern JA et al. Biomaterials (2018) 171(2) 230-246
A Method for Prostate and Breast Cancer Cell Spheroid Cultures Using Gelatin Methacryloyl-Based Hydrogels. Meinert C, Theodoropoulos C, Klein TJ et al. Methods Mol Biol (2018) 1786(1) 175-194
A humanised tissue-engineered bone model allows species-specific breast cancer-related bone metastasis in vivo. Quent V, Taubenberger AV, Reichert JC et al. J Tissue Eng Regen Med (2018) 12(2) 494-504
Magnetic resonance microimaging of cancer cell spheroid constructs Momot KI, Bas O, Holzapfel NP et al. Biomedical Spectroscopy and Imaging (2017) 5(1) 41-54For additional publications, please click here
Postdoctoral Research Assistants
Dr Juliana Candido
Eleonora Peerani, David Osuna de la Pena, Elena Tomas Bort
I joined the Centre for Cancer and Inflammation in March 2017. Until February 2017, I was leading the interdisciplinary 3-D Cancer Models Team at the Centre for Regenerative Medicine, at the Institute of Health and Biomedical Innovation in Brisbane, Australia.
I received my PhD from the Faculty of Chemistry, Technical University of Munich, Germany, and undertook my postdoctoral research training at Queensland University of Technology, EPFL and University of Chicago.